TapImmune Inc. (OTCMKTS:TPIV) is set to be one of the firms to present its products at the SeeThruEquity Fall MicroCap Investor Conference. The conference will be held at the Pershing Hub, Convene Grand Central in 101 Park Avenue, New York. The event will take place on September 10.
Highlights
TapImmune Inc. is a pharmaceutical company that immunotherapy treatments through innovative peptide and gene-based technology. The firm has been placing a lot of focus on vaccines for the treatment of metastatic disease as well as cancer and other infectious diseases. The specialized technology that the firm has been using to develop its treatment has been kind enough to place the company in a good position within the pharmaceutical industry.
The industry has been developing into a hostile battlefield as competition grows. For that reason, there has been a lot of mergers and acquisitions in the current year as firms try to secure their position in the market. TapImmune Inc. was lucky enough to secure a place at the investor conference because of the breast and ovarian cancer treatments that it has been working on.
Way forward
TapImmune’s CEO, Dr. Glynn Wilson stated that the firm has made significant progress in the Phase I drug trials for cancer treatment that the Taplmmune has been working on over the past year. He further added that the conference will provide an ideal opportunity for the firm to reveal more information about the phase I trials. The company is now headed towards phase II clinical trials.
The good news has cultivated a positive outcome on the stock market for the firm. Tapimmune Inc. (OTCMKTS:TPIV) closed on an upward trend in the midweek stock review thought the performance was not as impressive as the previous boom in June. The trend might have higher margins once the results of the phase I trials are revealed.
